Advisory Committee on Immunization Practices, 2619-2620 [2024-00674]

Download as PDF Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–6, Atlanta, Georgia 30329–4027. Telephone: (404) 718– 8833; Email: GAnderson@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–00675 Filed 1–12–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2024–0001] Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice and request for comment. AGENCY: In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment. DATES: The meeting will be held on February 28, 2024, from 8 a.m. to 5 p.m., EST and February 29, 2024, from 8 a.m. to 3 p.m., EST, (times subject to change; see the ACIP website for updates: https://www.cdc.gov/vaccines/acip/ index.html). Written comments must be received between February 1–22, 2024. ADDRESSES: You may submit comments, identified by Docket No. CDC–2024– 0001, by either of the methods listed below. CDC does not accept comments by email. • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Attn: Docket No. CDC– 2024–0001. ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 18:57 Jan 12, 2024 Jkt 262001 Instructions: All submissions received must include the Agency name and docket number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. The meeting will be webcast live via the World Wide Web. The webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/ index.html. FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Telephone: (404) 639–8836; Email: ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans. Matters To Be Considered: The agenda will include discussions on influenza vaccines, chikungunya vaccine, COVID– 19 vaccines, meningococcal vaccines, pneumococcal vaccines, polio vaccines, Human papillomavirus (HPV) vaccines, respiratory syncytial virus vaccines, a combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®), and vaccines to prevent diphtheria, tetanus, and pertussis. Recommendation votes are scheduled for influenza vaccines, COVID–19 vaccines, and chikungunya vaccine. A Vaccines for Children (VFC) PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 2619 vote is scheduled for vaccines to prevent diphtheria, tetanus, and pertussis. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/ meetings/. Meeting Information: The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: The docket will be opened to receive written comments on February 1–22, 2024. Written comments must be received by February 22, 2024. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the February 28–29, 2024, ACIP meeting must submit a request at https://www.cdc.gov/ vaccines/acip/meetings/ between February 1, 2024, and no later than 11:59 p.m., EST, February 22, 2024, according to the instructions provided. E:\FR\FM\16JAN1.SGM 16JAN1 2620 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by February 26, 2024. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may speak only once per meeting. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–00674 Filed 1–12–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Meeting of the Board of Scientific Counselors, National Center for Health Statistics Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting. AGENCY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS). This meeting is open to the public. Time will be available for public comment. DATES: The meeting will be held on March 6, 2024, from 11 a.m. to 5 p.m., EST. ADDRESSES: Instructions to access the live meeting broadcast will be posted here: https://www.cdc.gov/nchs/about/ bsc/bsc_meetings.htm. FOR FURTHER INFORMATION CONTACT: Rebecca Hines, M.H.S., Designated Federal Officer, Board of Scientific ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 18:57 Jan 12, 2024 Jkt 262001 Counselors, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Mailstop P–08, Hyattsville, Maryland 20782. Telephone: (301) 458–4715; Email: RSHines@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS) is charged with providing advice and making recommendations to the Secretary, Department of Health and Human Services; the Director, Centers for Disease Control and Prevention; and the Director, National Center for Health Statistics, regarding the scientific and technical program goals and objectives, strategies, and priorities of NCHS. Matters to be Considered: The meeting agenda will include an update from the NCHS Director; welcoming of new Board members; updates from NCHS programs; and discussion regarding current issues and topics. The Board will reserve time for public comment at the end of the day. Meeting times and agenda topics are subject to change as priorities dictate. Meeting Information: Please visit the BSC, NCHS website for details: https:// www.cdc.gov/nchs/about/bsc/bsc_ meetings.htm. Further information and the meeting agenda will be available on the website, including any agenda updates and the instructions for accessing the live meeting broadcast. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–00641 Filed 1–12–24; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60Day–24–1181; Docket No. CDC–2023– 0101] Proposed Data Collection Submitted for Public Comment and Recommendations Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Airline and Traveler Information Collection: Domestic Manifests and Passenger Locator Form. These data collection forms align with CDC’s regulatory and public health mission under the authorities listed in CDC regulations to allow CDC to collect passenger and crew information from travelers and airlines when there has been a confirmed or suspected case of communicable disease aboard a domestic or international flight that puts other travelers at public health risk. DATES: CDC must receive written comments on or before March 18, 2024. ADDRESSES: You may submit comments, identified by Docket No. CDC–2023– 0101 by either of the following methods: • Federal eRulemaking Portal: www.regulations.gov. Follow the instructions for submitting comments. • Mail: Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21–8, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to www.regulations.gov. Please note: Submit all comments through the Federal eRulemaking portal (www.regulations.gov) or by U.S. mail to the address listed above. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and SUMMARY: E:\FR\FM\16JAN1.SGM 16JAN1

Agencies

[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2619-2620]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00674]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2024-0001]


Advisory Committee on Immunization Practices

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with regulatory provisions, the Centers for 
Disease Control and Prevention (CDC) announces the following meeting of 
the Advisory Committee on Immunization Practices (ACIP). This meeting 
is open to the public. Time will be available for public comment.

DATES: The meeting will be held on February 28, 2024, from 8 a.m. to 5 
p.m., EST and February 29, 2024, from 8 a.m. to 3 p.m., EST, (times 
subject to change; see the ACIP website for updates: https://www.cdc.gov/vaccines/acip/).
    Written comments must be received between February 1-22, 2024.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0001, by either of the methods listed below. CDC does not accept 
comments by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, 
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2024-0001.
    Instructions: All submissions received must include the Agency name 
and docket number. All relevant comments received in conformance with 
the https://www.regulations.gov suitability policy will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.
    The meeting will be webcast live via the World Wide Web. The 
webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management 
Specialist, Advisory Committee on Immunization Practices, National 
Center for Immunization and Respiratory Diseases, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, 
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The Advisory Committee on Immunization Practices (ACIP) is 
charged with advising the Director, Centers for Disease Control and 
Prevention (CDC), on the use of immunizing agents. In addition, under 
42 U.S.C. 1396s, the Committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
for Children program, along with schedules regarding dosing interval, 
dosage, and contraindications to administration of vaccines. Further, 
under applicable provisions of the Affordable Care Act and section 2713 
of the Public Health Service Act, immunization recommendations of ACIP 
that have been approved by the Director, CDC, and appear on CDC 
immunization schedules generally must be covered by applicable health 
plans.
    Matters To Be Considered: The agenda will include discussions on 
influenza vaccines, chikungunya vaccine, COVID-19 vaccines, 
meningococcal vaccines, pneumococcal vaccines, polio vaccines, Human 
papillomavirus (HPV) vaccines, respiratory syncytial virus vaccines, a 
combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, 
Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and 
Hepatitis B vaccine (Vaxelis[supreg]), and vaccines to prevent 
diphtheria, tetanus, and pertussis. Recommendation votes are scheduled 
for influenza vaccines, COVID-19 vaccines, and chikungunya vaccine. A 
Vaccines for Children (VFC) vote is scheduled for vaccines to prevent 
diphtheria, tetanus, and pertussis. Agenda items are subject to change 
as priorities dictate. For more information on the meeting agenda, 
visit https://www.cdc.gov/vaccines/acip/meetings/.
    Meeting Information: The meeting will be webcast live via the World 
Wide Web. For more information on ACIP, please visit the ACIP website: 
https://www.cdc.gov/vaccines/acip/.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near-duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on February 1-22, 2024. Written comments must be 
received by February 22, 2024.
    Oral Public Comment: This meeting will include time for members of 
the public to make an oral comment. Oral public comment will occur 
before any scheduled votes, including all votes relevant to the ACIP's 
Affordable Care Act and Vaccines for Children Program roles. Priority 
will be given to individuals who submit a request to make an oral 
public comment before the meeting according to the procedures below.
    Procedure for Oral Public Comment: All persons interested in making 
an oral public comment at the February 28-29, 2024, ACIP meeting must 
submit a request at https://www.cdc.gov/vaccines/acip/meetings/ between February 1, 2024, and no later than 11:59 p.m., EST, 
February 22, 2024, according to the instructions provided.

[[Page 2620]]

    If the number of persons requesting to speak is greater than can be 
reasonably accommodated during the scheduled time, CDC will conduct a 
lottery to determine the speakers for the scheduled public comment 
session. CDC staff will notify individuals regarding their request to 
speak by email by February 26, 2024. To accommodate the significant 
interest in participation in the oral public comment session of ACIP 
meetings, each speaker will be limited to three minutes, and each 
speaker may speak only once per meeting.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-00674 Filed 1-12-24; 8:45 am]
BILLING CODE 4163-18-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.